Vir Biotechnology (VIR) Total Liabilities (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of Total Liabilities data on file, last reported at $212.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 19.36% year-over-year to $212.8 million; the trailing twelve-month figure through Mar 2026 stood at $212.8 million (down 19.36% YoY), and the FY2025 full-year result was $237.5 million, down 4.38% from the prior year.
• Total Liabilities retreated to $212.8 million in Q1 2026, from $237.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $886.1 million in Q1 2022 to a low of $212.8 million in Q1 2026.
• A 5-year average of $401.3 million and a median of $263.9 million in 2025 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities jumped 108.27% in 2022 and slumped 64.52% in 2024, its largest moves.
• Tracing VIR's Total Liabilities over 5 years: stood at $724.1 million in 2022, then tumbled by 54.59% to $328.8 million in 2023, then fell by 24.45% to $248.4 million in 2024, then decreased by 4.38% to $237.5 million in 2025, then retreated by 10.41% to $212.8 million in 2026.
• Business Quant data shows VIR's Total Liabilities at $212.8 million in Q1 2026, $237.5 million in Q4 2025, and $223.4 million in Q3 2025.